Amgen Sues Colorado Again as State Adopts Pay Cap on Enbrel (1)

Amgen Inc. filed a second lawsuit against a Colorado drug affordability panel for placing a state payment cap on its blockbuster drug Enbrel, challenging an action that it says will cause injuries that are no longer hypothetical to the company.

The complaint, filed Thursday in the US District Court for the District of Colorado, alleges the state’s Prescription Drug Affordability Board’s Oct. 3 vote to propose a cap on what health plans pay for Enbrel is unconstitutional.

The vote caps Enbrel’s price at $600 per 50 mg/ml unit, based on the current maximum fair price for the autoimmune treatment ...